Is the IL-10 promoter polymorphism at position -592 associated with immune system-related diseases?

Inflammation

Volumn 36, Issue 1, 2013, Pages 35-41

  Karimabad, Mojgan Noroozi ^a   Arababadi, Mohammad Kazemi ^a   Hakimizadeh, Elham ^a   Daredori, Hassan Yousefi ^a   Nazari, Mahmood ^a   Hassanshahi, Gholamhossein ^a   Kennedy, Derek ^b  

^a RAFSANJAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b GRIFFITH UNIVERSITY   (Australia)

Author keywords

asthma; diabetes; IL 10; multiple sclerosis; nephropathy; polymorphism

Indexed keywords

AUTOANTIGEN; INTERLEUKIN 10;

ASTHMA; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; CELL TYPE; GENE EXPRESSION REGULATION; GENE FUNCTION; HOMEOSTASIS; HUMAN; HYPERSENSITIVITY; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOPATHOLOGY; IMMUNOREGULATION; INTERLEUKIN 10 GENE; MACROPHAGE; MULTIPLE SCLEROSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PROMOTER REGION; REGULATORY T LYMPHOCYTE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TH2 CELL;

ASTHMA; DIABETES MELLITUS, TYPE 2; GENE EXPRESSION REGULATION; HUMANS; IMMUNE SYSTEM DISEASES; INTERLEUKIN-10; IRAN; MULTIPLE SCLEROSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC;

EID: 84872892497     PISSN: 03603997     EISSN: 15732576     Source Type: Journal    
DOI: 10.1007/s10753-012-9517-7     Document Type: Review

References (64)

1. Chiang, Y.J., H.K. Kole, K. Brown, et al. 2000. Cbl-b regulates the CD28 dependence of T-cell activation. Nature 403: 216-220. (Pubitemid 30050967)
2. Arababadi, M.K., B.N. Ahmadabadi, and D. Kennedy. 2012. Current information on the immunological status of occult hepatitis B infection. Transfusion. doi: 10.1111/j.1537-2995.2012.03575.x.
3. van Eden, W., A. Koets, P. van Kooten, et al. 2003. Immunopotentiating heat shock proteins: negotiators between innate danger and control of autoimmunity. Vaccine 21: 897-901. (Pubitemid 36126424)
4. Miyara, M., K. Wing, and S. Sakaguchi. 2009. Therapeutic approaches to allergy and autoimmunity based on FoxP3+ regulatory T-cell activation and expansion. The Journal of Allergy and Clinical Immunology 123: 749-755. quiz 756-747.
5. Li, Y.P., V. Latger-Canard, L. Marchal, et al. 2006. The regulatory role of dendritic cells in the immune tolerance. Biomedical Materials and Engineering 16: S163-S170.
6. Karjalainen, J., J. Hulkkonen, M.M. Nieminen, et al. 2003. Interleukin-10 gene promoter region polymorphism is associated with eosinophil count and circulating immunoglobulin E in adult asthma. Clinical and Experimental Allergy 33: 78-83. (Pubitemid 36114911)
7. Sawcer, S., G. Hellenthal, M. Pirinen, et al. 2011. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476: 214-219.
8. Arababadi, M.K., R. Mosavi, H. Khorramdelazad, et al. 2010. Cytokine patterns after therapy with Avonex(R), Rebif(R), Betaferon(R) and CinnoVex in relapsing-remitting multiple sclerosis in Iranian patients. Biomarkers in Medicine 4: 755-759.
9. Arababadi, M.K., G. Hassanshahi, H. Azin, et al. 2010. No association between CCR5 â‰VERIFICATION 32 mutation and multiple sclerosis in patients of south-eastern of Iran. Laboratory Medicine 41: 31-33.
10. Arababadi, M.K., R. Mosavi, H. Teimori, et al. 2011. Association of IL-4 polymorphisms with multiple sclerosis in south-eastern Iranian patients. Annals of Saudi Medicine 32(2): 127-130.
11. Arababadi, M.K., H. Abousaidi, G. Hassanshahi, et al. 2011. Association of exon 9 but not intron 8 VDR polymorphisms with asthma in south-eastern Iranian patients. Iranian Journal of Basic Medical Science 14: 107-115.
12. Cookson, W. 1999. The alliance of genes and environment in asthma and allergy. Nature 402: B5-B11.
13. Orihara, K., N. Dil, V. Anaparti, et al. 2011. What's new in asthma pathophysiology and immunopathology? Expert Review of Respiratory Medicine 4: 605-629.
14. Yaghini, N., M. Mahmoodi, G. Asadikaram, et al. 2011. Genetic variation of IL-12B (+1188 region) is associated with its decreased circulating levels and susceptibility to type 2 diabetes: A study on south-eastern Iranian diabetic patients. Biomarkers in Medicine 6(1): 89-95.
15. Cruz, M., C. Maldonado-Bernal, R. Mondragon-Gonzalez, et al. 2008. Glycine treatment decreases proinflammatory cytokines and increases interferon-gamma in patients with type 2 diabetes. Journal of Endocrinological Investigation 31: 694-699.
16. Yaghini, N., M. Mahmoodi, G. Asadikaram, et al. 2011. Serum levels of Interleukin 10 (IL-10) in patients with type 2 diabetes. Iranian Red Crescent Medical Journal 13(10): 752.
17. Arababadi, M.K., R. Nosratabadi, G. Hassanshahi, et al. 2009. Nephropathic complication of type-2 diabetes is following pattern of autoimmune diseases? Diabetes Research and Clinical Practice 87: 33-37.
18. Arababadi, M.K., A.A. Pourfathollah, S. Daneshmandi, et al. 2009. Evaluation of relation between IL-4 and IFN-g polymorphisms and type 2 diabetes. Iranian Journal of Basic Medical Science 12: 100-104.
19. Arababadi, M.K., N. Naghavi, G. Hassanshahi, et al. 2009. Is CCR5-Delta32 mutation associated with diabetic nephropathy in type 2 diabetes? Annals of Saudi Medicine 29: 413.
20. Groux, H., and F. Cottrez. 2003. The complex role of interleukin-10 in autoimmunity. Journal of Autoimmunity 20: 281-285. (Pubitemid 36677519)
21. Howell, W.M., and M.J. Rose-Zerilli. 2006. Interleukin-10 polymorphisms, cancer susceptibility and prognosis. Familial Cancer 5: 143-149. (Pubitemid 43824470)
22. Sabat, R., G. Grutz, K. Warszawska, et al. 2010. Biology of interleukin-10. Cytokine & Growth Factor Reviews 21: 331-344.
23. Moore, K.W., R. de Waal Malefyt, R.L. Coffman, et al. 2001. Interleukin-10 and the interleukin-10 receptor. Annual Review of Immunology 19: 683-765. (Pubitemid 32368050)
24. Booy, R., S. Nadel, M. Hibberd, et al. 1997. Genetic influence on cytokine production in meningococcal disease. Lancet 349: 1176. (Pubitemid 27168565)
25. Zhang, Y., J. Zhang, C. Tian, et al. 2011. The -1082G/A polymorphism in IL-10 gene is associated with risk of Alzheimer's disease: A meta-Analysis. Journal of Neurological Sciences 303: 133-138.
26. Lopez, P., C. Gutierrez, and A. Suarez. 2010. IL-10 and TNFalpha genotypes in SLE. Journal of Biomedicine and Biotechnology 2010: 838390.
27. Scapini, P., C. Lamagna, Y. Hu, et al. 2011. B cell-derived IL-10 suppresses inflammatory disease in Lyn-deficient mice. Proceedings of the National Academy of Sciences of the United States of America 2011: 12.
28. Li, M.O., and R.A. Flavell. 2008. Contextual regulation of inflammation: A duet by transforming growth factor-beta and interleukin-10. Immunity 28: 468-476. (Pubitemid 351467045)
29. Arababadi, M.K. 2010. Interleukin-4 gene polymorphisms in type 2 diabetic patients with nephropathy. Iranian Journal of Kidney Diseases 4: 302-306.
30. Nosratabadi, R., M.K. Arababadi, V.A. Salehabad, et al. 2010. Polymorphisms within exon 9 but not intron 8 of the vitamin D receptor are associated with the nephropathic complication of type-2 diabetes. International Journal of Immunogenetics 37: 1-5.
31. Arababadi, M.K., M. Mirzaei, S.M.A. Sajadi, et al. 2011. Interleukin (IL)-10 gene polymorphisms is associated with type 2 diabetes with and without nephropathy: A study of patients from the South-East region of Iran. Inflammation 35(3): 797-802.
32. Chang, J.H., H.R. Cha, D.S. Lee, et al. 1,25-Dihydroxyvitamin D3 inhibits the differentiation and migration of T(H)17 cells to protect against experimental autoimmune encephalomyelitis. PLoS One 5: e12925.
33. Mtiraoui, N., I. Ezzidi, M. Kacem, et al. 2009. Predictive value of interleukin-10 promoter genotypes and haplotypes in determining the susceptibility to nephropathy in type 2 diabetes patients. Diabetes/Metabolism Research and Reviews 25: 57-63.
34. Kung, W.J., C.C. Lin, S.H. Liu, et al. 2011. Association of interleukin-10 polymorphisms with cytokines in type 2 diabetic nephropathy. Diabetes Technology & Therapeutics 12: 809-813.
35. Ezzidi, I., N. Mtiraoui, M. Kacem, et al. 2009. Interleukin-10-592C/A, -819C/T and -1082A/G promoter variants affect the susceptibility to nephropathy in Tunisian type 2 diabetes (T2DM) patients. Clinical Endocrinology 70: 401-407.
36. Ishii, M., G. Hasegawa, M. Fukui, et al. 2005. Clinical and genetic characteristics of diabetic patients with high-titer (>10,000 U/ml) of antibodies to glutamic acid decarboxylase. Immunology Letters 99: 180-185. (Pubitemid 40973771)
37. Scarpelli, D., M. Cardellini, F. Andreozzi, et al. 2006. Variants of the interleukin-10 promoter gene are associated with obesity and insulin resistance but not type 2 diabetes in caucasian italian subjects. Diabetes 55: 1529-1533. (Pubitemid 44195398)
38. Ascherio, A., K.L. Munger, K.C. Simon. Vitamin D and multiple sclerosis. Lancet Neurology 9: 599-612.
39. Teunissen, C.E., J. Killestein, and G. Giovannoni. 2007. Biomarker research in multiple sclerosis: Addressing axonal damage and heterogeneity. Biomarkers in Medicine 1: 111-119.
40. Glass, C.K., K. Saijo, B. Winner, et al. 2010. Mechanisms underlying inflammation in neurodegeneration. Cell 140: 918-934.
41. Nosratabadi, R., B.N. Ahmadabadi, M.K. Arababadi, et al. 2011. Association of polymorphism in the -592 region of IL-10 with multiple sclerosis in south-eastern Iranian patients. Iranian Red Crescent Medical Journal 32(2): 127-130.
42. Almeras, L., B. Meresse, J. Seze, et al. 2002. Interleukin-10 promoter polymorphism in multiple sclerosis: Association with disease progression. European Cytokine Network 13: 200-206. (Pubitemid 34747920)
43. Forte, G.I., P. Ragonese, G. Salemi, et al. 2006. Search for genetic factors associated with susceptibility to multiple sclerosis. Annals of the New York Academy of Sciences 1067: 264-269. (Pubitemid 43806333)
44. Luomala, M., T. Lehtimaki, H. Huhtala, et al. 2003. Promoter polymorphism of IL-10 and severity of multiple sclerosis. Acta Neurologica Scandinavica 108: 396-400. (Pubitemid 37464118)
45. Mihailova, S., M. Ivanova, A. Mihaylova, et al. 2005. Pro- and anti-inflammatory cytokine gene polymorphism profiles in Bulgarian multiple sclerosis patients. Journal of Neuroimmunology 168: 138-143. (Pubitemid 41396411)
46. Wergeland, S., A. Beiske, H. Nyland, et al. 2005. IL-10 promoter haplotype influence on interferon treatment response in multiple sclerosis. European Journal of Neurology 12: 171-175. (Pubitemid 40278522)
47. Azarpira, N., A. Borhani Haghighi, M. Pourjafar, et al. 2010. Interleukin 10 gene polymorphism in Iranian patients with multiple sclerosis. Acta Neurologica Taiwanica 19: 107-111.
48. Pickard, C., C. Mann, P. Sinnott, et al. 1999. Interleukin-10 (IL10) promoter polymorphisms and multiple sclerosis. Journal of Neuroimmunology 101: 207-210. (Pubitemid 29516463)
49. Sandford, A.J., S. Zhu, T.R. Bai, et al. 2001. The role of the C-C chemokine receptor-5 Delta32 polymorphism in asthma and in the production of regulated on activation, normal T cells expressed and secreted. The Journal of Allergy and Clinical Immunology 108: 69-73. (Pubitemid 32662234)
50. Zietkowski, Z., M.M. Tomasiak, R. Skiepko, et al. 2008. RANTES in exhaled breath condensate of stable and unstable asthma patients. Respiratory Medicine 102: 1198-1202.
51. Abousaidi, H., R. Vazirinejad, M.K. Arababadi, et al. 2011. Lack of association between chemokine receptor 5 (CCR5) C32 mutation and pathogenesis of asthma: A study on Iranian asthma patients. Southern Medical Journal 104: 422-425.
52. Pukelsheim, K., T. Stoeger, D. Kutschke, et al. 2010. Cytokine profiles in asthma families depend on age and phenotype. PLoS One 5: e14299.
53. Hakimizadeh, E., M.K. Arababadi, G. Hassanshahi, et al. 2012. Association of -592 region of IL-10 polymorphisms with asthma in south-eastern Iranian patients. Clinical Laboratory 58: 267-271.
54. Zhang, J., H. Chen, L. Hu, et al. 2002. Correlation between polymorphism of IL-4 and IL-10 gene promoter and childhood asthma and their impact upon cytokine expression. Zhonghua Yi Xue Za Zhi 82: 114-118.
55. Movahedi, M., S.A. Mahdaviani, N. Rezaei, et al. 2008. IL-10, TGF-beta, IL-2, IL-12, and IFN-gamma cytokine gene polymorphisms in asthma. The Journal of Asthma 45: 790-794.
56. Hobbs, K., J. Negri, M. Klinnert, et al. 1998. Interleukin-10 and transforming growth factor-beta promoter polymorphisms in allergies and asthma. American Journal of Respiratory and Critical Care Medicine 158: 1958-1962. (Pubitemid 29008839)
57. Immervoll, T., S. Loesgen, G. Dutsch, et al. 2001. Fine mapping and single nucleotide polymorphism association results of candidate genes for asthma and related phenotypes. Human Mutation 18: 327-336. (Pubitemid 32916863)
58. Kim, S.H., E.M. Yang, H.N. Lee, et al. 2009. Combined effect of IL-10 and TGF-beta1 promoter polymorphisms as a risk factor for aspirin-intolerant asthma and rhinosinusitis. Allergy 64: 1221-1225.
59. Trajkov, D., J. Mirkovska-Stojkovikj, T. Arsov, et al. 2008. Association of cytokine gene polymorphisms with bronchial asthma in Macedonians. Iranian Journal of Allergy, Asthma, and Immunology 7: 143-156.
60. Zedan, M., A. Settin, M.K. Farag, et al. 2008. Gene polymorphisms of tumor necrosis factor alpha-308 and interleukin-10-1082 among asthmatic Egyptian children. Allergy and Asthma Proceedings 29: 268-273.
61. Chatterjee, R., J. Batra, A. Kumar, et al. 2005. Interleukin-10 promoter polymorphisms and atopic asthma in North Indians. Clinical and Experimental Allergy 35: 914-919. (Pubitemid 41032540)
62. Kazemi Arababadi, M., M. Reza Mirzaei, S.M. Ali Sajadi, et al. Interleukin (IL)-10 gene polymorphisms are associated with type 2 diabetes with and without nephropathy: A study of patients from the southeast region of Iran. Inflammation 35: 797-802.
63. Kung, W.J., C.C. Lin, S.H. Liu, et al. Association of interleukin-10 polymorphisms with cytokines in type 2 diabetic nephropathy. Diabetes Technology & Therapeutics 12: 809-813.
64. Hakimizadeh, E., M.K. Arababadi, G. Hassanshahi, et al. Association of -592 region of IL-10 polymorphisms with asthma in south-eastern Iranian patients. Clinical Laboratory 58: 267-271.